Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?

ABSTRACT:

Background

Alzheimer's Disease (AD), the most common type of dementia, is a chronic, progressive, and neurodegenerative brain discomfort that causes the be damage to brain cells. Although there is no definitive treatment for AD, various drug treatments are used to reduce and control the symptoms of the disease. Developed for the treatment of mild-stage Alzheimer's patients, Aducanumab is the only drug approved by the Food and Drug Administration (FDA) in the past two decades. However, the cost is very high and, in many countries, Aducanumab has not been approved due to insufficient clinical efficacy and lack of evidence yet. This study aims to analyze the cost-effectiveness of Aducanumab, which was developed for the treatment of mild-stage AD, from the patient's perspective.

Met

SUBMITTER: Yigit V 

PROVIDER: S-EPMC10410945 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature